Market Research Logo

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2016

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2016’, provides an overview of the Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)
  • The report reviews pipeline therapeutics for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) therapeutics and enlists all their major and minor projects
  • The report assesses Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Overview
Therapeutics Development
Pipeline Products for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Overview
Pipeline Products for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Comparative Analysis
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Therapeutics under Development by Companies
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Therapeutics under Investigation by Universities/Institutes
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Products under Development by Companies
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Products under Investigation by Universities/Institutes
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Companies Involved in Therapeutics Development
4SC AG
AbbVie Inc
Acetylon Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc.
ADC Therapeutics Sarl
Affimed GmbH
Amgen Inc.
Arno Therapeutics, Inc.
Bellicum Pharmaceuticals, Inc.
Bristol-Myers Squibb Company
Celgene Corporation
Cell Medica Limited
Cellular Biomedicine Group, Inc.
Constellation Pharmaceuticals, Inc.
Curis, Inc.
Faron Pharmaceuticals Oy
Gamida Cell Ltd.
Incyte Corporation
Merck & Co., Inc.
Merck KGaA
Mesoblast Limited
Millennium Pharmaceuticals Inc
Mirati Therapeutics Inc.
Molecular Templates Inc.
NantKwest, Inc.
Ono Pharmaceutical Co., Ltd.
Pfizer Inc.
Philogen S.p.A.
Polyphor Ltd.
Rich Pharmaceuticals, Inc.
Seattle Genetics, Inc.
Selvita S.A.
Sigma-Tau S.p.A.
Spectrum Pharmaceuticals, Inc.
Stemline Therapeutics, Inc.
Taiwan Liposome Company, Ltd.
Takeda Pharmaceutical Company Limited
TG Therapeutics, Inc.
Theravectys SA
TRACON Pharmaceuticals, Inc.
Trillium Therapeutics Inc.
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(INCB-039110 + INCB-040093) - Drug Profile
ADCT-301 - Drug Profile
AFM-13 - Drug Profile
Alocrest - Drug Profile
AR-42 - Drug Profile
avelumab - Drug Profile
azacitidine - Drug Profile
balixafortide - Drug Profile
BC-8Y90 - Drug Profile
BMS-986016 - Drug Profile
BPX-501 - Drug Profile
brentuximab vedotin - Drug Profile
CBM-C30.1 - Drug Profile
Cellular Immunotherapy for Hodgkin Lymphoma and Non-Hodgkin Lymphoma - Drug Profile
Cellular Immunotherapy for Oncology - Drug Profile
Cellular Immunotherapy for Oncology - Drug Profile
Cellular Immunotherapy to Target CD30 for Hodgkin and Non-Hodgkin Lymphomas - Drug Profile
Cellular Immunotherapy to Target CD30 for Hodgkin and Non-Hodgkin Lymphomas - Drug Profile
Cellular Immunotherapy to Target GM-CSF for Hodgkin Lymphoma and Chronic Lymphocytic Leukemia - Drug Profile
Cellular Immunotherapy to Target GM-CSF for Solid Tumor and Hematological Cancer - Drug Profile
Cellular Immunotherapy to Target LMP, BARF-1 and EBNA1 for EBV Associated Cancers and Infection - Drug Profile
Cellular Immunotherapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases - Drug Profile
Cellular Immunotherapy to Target NY-ESO-1, MAGEA4, PRAME, Survivin and Synovial Sarcoma X for Oncology - Drug Profile
CMD-003 - Drug Profile
CPI-0610 - Drug Profile
CUDC-907 - Drug Profile
Epstein-Barr virus vaccine - Drug Profile
Ferritarg - Drug Profile
FP-1305 - Drug Profile
haNK Program - Drug Profile
ibrutinib - Drug Profile
INCB-40093 - Drug Profile
Indimitecan - Drug Profile
Indotecan hydrochloride - Drug Profile
Iomab-B - Drug Profile
ipilimumab - Drug Profile
ixazomib citrate - Drug Profile
lirilumab - Drug Profile
MK-2206 - Drug Profile
mocetinostat - Drug Profile
Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies and Bacterial Infections - Drug Profile
MPC-CBE - Drug Profile
MT-17000 - Drug Profile
NiCord - Drug Profile
nivolumab - Drug Profile
NL-101 - Drug Profile
ONX-0801 - Drug Profile
pembrolizumab - Drug Profile
PF-06801591 - Drug Profile
PNK-007 - Drug Profile
procarbazine hydrochloride - Drug Profile
radretumab - Drug Profile
resminostat - Drug Profile
ricolinostat - Drug Profile
RP-323 - Drug Profile
ruxolitinib phosphate - Drug Profile
sapanisertib - Drug Profile
SEA-CD40 - Drug Profile
SEL-24B489 - Drug Profile
SL-101 - Drug Profile
SL-501 - Drug Profile
Small Molecule to Inhibit ADAM-10 for Hodgkin Lymphoma - Drug Profile
temsirolimus - Drug Profile
TGR-1202 - Drug Profile
TRC-102 - Drug Profile
TTI-621 - Drug Profile
Vaccine for Nasopharyngeal Cancer and Hodgkin Lymphoma - Drug Profile
vinorelbine tartrate - Drug Profile
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Dormant Projects
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Discontinued Products
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), H2 2016
Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Investigation by Universities/Institutes, H2 2016
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by 4SC AG, H2 2016
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by AbbVie Inc, H2 2016
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2016
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Actinium Pharmaceuticals, Inc., H2 2016
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by ADC Therapeutics Sarl, H2 2016
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Affimed GmbH , H2 2016
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Amgen Inc., H2 2016
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Arno Therapeutics, Inc., H2 2016
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2016
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Bristol-Myers Squibb Company, H2 2016
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Celgene Corporation, H2 2016
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Cell Medica Limited, H2 2016
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Cellular Biomedicine Group, Inc., H2 2016
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Constellation Pharmaceuticals, Inc., H2 2016
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Curis, Inc., H2 2016
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Faron Pharmaceuticals Oy, H2 2016
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Gamida Cell Ltd., H2 2016
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Incyte Corporation, H2 2016
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Merck & Co., Inc., H2 2016
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Merck KGaA, H2 2016
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Mesoblast Limited, H2 2016
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Mirati Therapeutics Inc., H2 2016
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Molecular Templates Inc., H2 2016
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by NantKwest, Inc., H2 2016
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Pfizer Inc., H2 2016
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Philogen S.p.A., H2 2016
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Polyphor Ltd., H2 2016
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Rich Pharmaceuticals, Inc., H2 2016
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Seattle Genetics, Inc., H2 2016
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Selvita S.A., H2 2016
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Sigma-Tau S.p.A., H2 2016
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2016
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Stemline Therapeutics, Inc., H2 2016
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Taiwan Liposome Company, Ltd., H2 2016
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by TG Therapeutics, Inc., H2 2016
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Theravectys SA, H2 2016
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by TRACON Pharmaceuticals, Inc., H2 2016
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Trillium Therapeutics Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Dormant Projects, H2 2016
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Dormant Projects (Contd..1), H2 2016
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Dormant Projects (Contd..2), H2 2016
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Dormant Projects (Contd..3), H2 2016
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Discontinued Products, H2 2016
List of Figures
Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), H2 2016
Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report